![]() |
|
|
Vol. 290, Issue 3, 1065-1079, September 1999
Department of Pharmacology and Toxicology, Medical College of
Virginia, Virginia Commonwealth University, Richmond, Virginia (B.R.M.,
R.J., R.W., J.L.W.); Department of Chemistry, Clemson University,
Clemson, South Carolina (J.W.H.); and Organix, Inc., Woburn,
Massachusetts (P.J.C., B.S., R.K.R.)
Structure-activity relation studies have established that the alkyl
side chain in tetrahydrocannabinol (THC) plays a crucial role in the
activation of the cannabinoid receptor. Unfortunately, the flexible
nature of this side chain has hampered efforts to elucidate the precise
nature of the interaction of THC with its receptors. Therefore, a
series of analogs with structurally restrained side chains of varying
length was synthesized and evaluated for pharmacological potency in
mice and for receptor affinity. The introduction of cis
double bonds inserted rigid angles, whereas triple bonds developed
regions of planarity. Receptor affinity for the acetylenic and
saturated side chains were the same, whereas double bond substitution
increased affinity 10-fold. Moreover, the relationship between receptor
affinity and potency was 10-fold less than that of
8-THC
in the case of some acetylenic derivatives, whereas changing the triple
bond to a double bond restored the potency/affinity ratio.
Additionally, an acetylene at C2-C3 in the octyl and nonyl side chains
favored antinociception by as much as 70-fold. Surprisingly, several
high-affinity acetylenic derivatives, especially those with cyano
substitutions at the terminus of the side chain, were partial agonists
or were inactive. Some of these low-efficacy, high-affinity ligands
elicited antagonistic activity. The finding that manipulations of the
side chain produces high- affinity ligands with either antagonist,
partial agonist, or full agonist effects reveals a critical structural
feature for receptor activation.
This article has been cited by other articles:
![]() |
R. E. Vann, C. D. Cook, B. R. Martin, and J. L. Wiley Cannabimimetic Properties of Ajulemic Acid J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 678 - 686. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. R. Martin, J. L. Wiley, I. Beletskaya, L. J. Sim-Selley, F. L. Smith, W. L. Dewey, J. Cottney, J. Adams, J. Baker, D. Hill, et al. Pharmacological Characterization of Novel Water-Soluble Cannabinoids J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1230 - 1239. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. P. Picone, A. D. Khanolkar, W. Xu, L. A. Ayotte, G. A. Thakur, D. P. Hurst, M. E. Abood, P. H. Reggio, D. J. Fournier, and A. Makriyannis (-)-7'-Isothiocyanato-11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM841), a High-Affinity Electrophilic Ligand, Interacts Covalently with a Cysteine in Helix Six and Activates the CB1 Cannabinoid Receptor Mol. Pharmacol., December 1, 2005; 68(6): 1623 - 1635. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Wiley, R. G. Jefferson, M. C. Grier, A. Mahadevan, R. K. Razdan, and B. R. Martin Novel Pyrazole Cannabinoids: Insights into CB1 Receptor Recognition and Activation J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 1013 - 1022. [Abstract] [Full Text] |
||||